Comparison of CYP2D metabolism and hepatotoxicity of the myocardial metabolic agent perhexiline in Sprague–Dawley and Dark Agouti rats

References

• Abozguia K, Elliott P, McKenna W, et al. (2010). Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122:1562–9
   PubMed Web of Science ®Google Scholar
• Amoah AG, Gould BJ, Parke DV, Lockhart JD. (1986). Further studies on the pharmacokinetics of perhexiline maleate in humans. Xenobiotica 16:63–8
   PubMed Web of Science ®Google Scholar
• Barclay ML, Sawyers SM, Begg EJ, et al. (2003). Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. Pharmacogenetics 13:627–32
   PubMedGoogle Scholar
• Barham HM, Lennard MS, Tucker GT. (1994). An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem Pharmacol 47:1295–307
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N, et al. (1990). Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 81:1260–70
   PubMed Web of Science ®Google Scholar
• Cooper RG, Evans DAP, Whibley EJ. (1984). Polymorphic hydroxylation of perhexiline maleate in man. J Med Genet 21:27–33
   PubMed Web of Science ®Google Scholar
• Davies BJ, Herbert MK, Coller JK, et al. (2006a). Determination of the 4-monohydroxy metabolites of perhexiline in human plasma, urine and liver microsomes by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 843:302–9
   PubMed Web of Science ®Google Scholar
• Davies BJ, Herbert MK, Culbert JA, et al. (2006b). Enantioselective assay for the determination of perhexiline enantiomers in human plasma by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 832:114–20
   PubMed Web of Science ®Google Scholar
• Davies BJ, Coller JK, Somogyi AA, et al. (2007). CYP2B6, CYP2D6, and CYP3A4 catalyze the primary oxidative metabolism of perhexiline enantiomers by human liver microsomes. Drug Metab Dispos 35:128–38
   PubMed Web of Science ®Google Scholar
• Davies BJ, Herbert MK, Coller JK, et al. (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. Br J Clin Pharmacol 65:347–54
   Google Scholar
• Fragasso G, Salerno A, Spoladore R, et al. (2008). Metabolic therapy of heart failure. Curr Pharm Des 14:2582–91
   Google Scholar
• Gould BJ, Amoah AG, Parke DV. (1986). Stereoselective pharmacokinetics of perhexiline. Xenobiotica 16:491–502
   PubMed Web of Science ®Google Scholar
• Hiroi T, Chow T, Imaoka S, Funae Y. (2002). Catalytic specificity of CYP2D isoforms in rat and human. Drug Metab Dispos 30:970–6
   PubMed Web of Science ®Google Scholar
• Horowitz JD, Chirkov YY. (2010). Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation. Circulation 122:1547–9
   PubMed Web of Science ®Google Scholar
• Horowitz JD, Sia ST, Macdonald PS, et al. (1986). Perhexiline maleate treatment for severe angina pectoris – correlations with pharmacokinetics. Int J Cardiol 13:219–29
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2005). Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. (2007). Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526
   PubMed Web of Science ®Google Scholar
• Inglis SC, Herbert MK, Davies BJ, et al. (2007). Effect of CYP2D6 metabolizer status on the disposition of the (+) and (−) enantiomers of perhexiline in patients with myocardial ischaemia. Pharmacogenet Genom 17:305–12
   PubMed Web of Science ®Google Scholar
• Jones TE, Morris RG, Horowitz JD. (2004). Concentration-time profile for perhexiline and hydroxyperhexiline in patients at steady state. Br J Clin Pharmacol 57:263–9
   Google Scholar
• Kennedy JA, Unger SA, Horowitz JD. (1996). Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52:273–80
   PubMed Web of Science ®Google Scholar
• Kodde IF, van der Stok J, Smolenski RT, de Jong JW. (2007). Metabolic and genetic regulation of cardiac energy substrate preference. Comp Biochem Physiol A Mol Integr Physiol 146:26–39
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. (2005). Pharmacokinetics and metabolism of metoprolol and propranolol in the female DA and female Wistar rat: the female DA rat is not always an animal model for poor metabolizers of CYP2D6. J Pharm Sci 94:397–408
   PubMed Web of Science ®Google Scholar
• Lee L, Campbell R, Scheuermann-Freestone M, et al. (2005). Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112:3280–8
   PubMed Web of Science ®Google Scholar
• Leeson GA, Lang JF, Zeiger AV, et al. (1969). Excretion, blood levels and tissue retention of perhexiline-14C maleate in dogs. Pharmacologist 11:280
   Google Scholar
• Matsunaga E, Zanger UM, Hardwick JP, et al. (1989). The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. Biochemistry 28:7349–55
   PubMed Web of Science ®Google Scholar
• Meier C, Wahllaender A, Hess CW, Preisig R. (1986). Perhexiline-induced lipidosis in the dark Agouti (DA) rat. An animal model of genetically determined neurotoxicity. Brain 109:649–60
   Google Scholar
• Morgan MY, Reshef R, Shah RR, et al. (1984). Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 25:1057–64
   PubMed Web of Science ®Google Scholar
• Ohishi N, Imaoka S, Suzuki T, Funae Y. (1993). Characterization of two P-450 isozymes placed in the rat CYP2D subfamily. Biochim Biophys Acta 1158:227–36
   PubMedGoogle Scholar
• Poupon R, Rosenztajn L, de Saint-Maur PP, et al. (1980). Perhexiline maleate-associated hepatic injury prevalence and characterisitcs. Digestion 20:145–50
   Google Scholar
• Sachse C, Brockmoller J, Bauer S, Roots I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–95
   PubMed Web of Science ®Google Scholar
• Sallustio BC, Westley IS, Morris RG. (2002). Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 54:107–14
   PubMed Web of Science ®Google Scholar
• Schulz-Utermoehl T, Bennett AJ, Ellis SW, et al. (1999). Polymorphic debrisoquine 4-hydroxylase activity in the rat is due to differences in CYP2D2 expression. Pharmacogenetics 9:357–66
   PubMedGoogle Scholar
• Singh A, Gilroy C, Chu I, Villeneuve DC. (1997). Toxicity of PCB 105 in the rat liver: an ultrastructural and biochemical study. Ultrastruct Pathol 21:143–51
   PubMed Web of Science ®Google Scholar
• Singlas E, Goujet MA, Simon P. (1978). Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. Eur J Clin Pharmacol 14:195–201
   PubMed Web of Science ®Google Scholar
• Unger SA, Robinson MA, Horowitz JD. (1997). Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust N Z J Med 27:24–8
   PubMedGoogle Scholar
• Willoughby SR, Stewart S, Chirkov YY, et al. (2002). Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J 23:1946–54
   PubMed Web of Science ®Google Scholar
• Wright GJ, Leeson GA, Zeiger AV, Lang JF. (1973). The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad Med J 49:8–15
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Tasaki T, Nakamura A, et al. (1998). Molecular basis of the Dark Agouti rat drug oxidation polymorphism: importance of CYP2D1 and CYP2D2. Pharmacogenetics 8:73–82
   PubMedGoogle Scholar
• Zanger UM, Raimundo S, Eichelbaum M. (2004). Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369:23–37
   PubMed Web of Science ®Google Scholar
• Zysset T, Zeugin T, Kupfer A. (1988). In-vivo and in-vitro dextromethorphan metabolism in SD and DA rat. An animal model of the debrisoquine-type polymorphic oxidation in man. Biochem Pharmacol 37:3155–60
   PubMed Web of Science ®Google Scholar